protego-bio Research by SuperAGI

Company Overview

Protego Biopharma is a biotechnology company headquartered in San Diego, California. Founded in 2012, it specializes in discovering and developing first-in-class small-molecule therapeutics focused on reprogramming protein folding. This innovative approach targets diseases related to protein misfolding, which are complex and currently have limited treatment options. Protego's endeavors are backed by strong human genetic rationale, ensuring that potential therapeutics are both safe and effective. The company's key therapeutic targets include systemic amyloid diseases and other conditions linked with misfolded proteins.

Protego Biopharma secured $51 million through a Series A financing round co-led by Vida Ventures, MPM Capital, and Lightspeed Venture Partners. This funding is designated for advancing Protego's novel class of disease-modifying drugs into early-stage clinical trials and broadening its discovery platform. The company reports an annual revenue of $2.6 million and employs 34 individuals. Recent growth trends highlight a 31% increase in its workforce, indicating significant developmental progress and enhanced operational capabilities.

Leadership Team

Brent Warner - Chief Executive Officer

Appointed in April 2024, Brent Warner brings over 15 years of expertise in the biopharmaceutical sector, with particular emphasis on rare diseases and gene therapy. Recognized as a notable biotech leader, he was listed among the "202 under 40" by Endpoints News.

Mike Petrassi - Chief Scientific Officer

Mike Petrassi heads Protego Biopharma's scientific ventures, leveraging his profound experience in medicinal and organic chemistry to target protein misfolding through pharmacological chaperones.

Chris Weyrer, M.D., Ph.D. - Acting Chief Business Officer

Serving additionally as a principal at Vida Ventures, Chris Weyrer contributes to Protego Biopharma's corporate strategy drawing from his robust medical and scientific background from Harvard Medical School.

Deborah Tower, CPA - Vice President of Finance & Administration

Deborah Tower ensures efficient financial operations and strategic planning, drawing from her extensive background in biotechnology finance.

Scientific Advisory Board

Chaired by Jeffrey W. Kelly, Ph.D., a preeminent figure in protein misfolding research and co-founder of FoldRx, Protego's Scientific Advisory Board comprises experts including Jason Gestwicki, Ph.D., Joel Buxbaum, M.D., Luke Wiseman, Ph.D., Madhu Natarajan, Ph.D., Richard Labaudinière, Ph.D., and Wendy Young, Ph.D. Their combined expertise enhances the company's efforts in developing therapeutics for protein misfolding diseases.

Competitor Analysis

Competitive Landscape

Protego Biopharma operates within a highly competitive biotech and pharmaceutical arena. Significant competitors include:

DiaCarta: Specializes in precision diagnostics with $4.4 million in revenue and 57 employees. They have secured $53 million in funding, focusing on personalized diagnostics and clinical sample testing.

Mission Bio: Known for its single-cell multi-omics platform, Mission Bio records $21.2 million in revenue with 137 employees, focusing extensively on cancer research.

Quadrants Scientific: Offers technical and regulatory consultancy with $0.9 million revenue and 6 employees. While smaller in scale, they influence market share in validation services.

Other notable competitors include Cedilla Therapeutics, Protomer Technologies, and ReAx Biotechnologies, contributing to competitive pressures through their innovations and market presence.

Strategic Positioning

Protego's niche focus on small-molecule therapeutics for protein misfolding positions it uniquely within the intersection of cutting-edge biotechnology and critical medical requirements. Its funding profile indicates a strategic prioritization towards research and development, which is instrumental for anticipated breakthroughs. Despite being smaller than certain competitors, Protego's significant employee growth suggests internal enhancements to sustain innovation and cater to market needs. Monitoring competitor advancements, particularly those of DiaCarta and Mission Bio, remains pivotal for maintaining a competitive edge.